

Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Horizon Europe

Generated at: October 8, 2026

● OPEN

Code

HORIZON-MISS-2027-02-CANCER-05

Scope

International

Location

Europe

Curator

Marlene Faria

Financial Details

Support type

Non-Refundable

Maximum Funding Rate

100%

Budget

26M€

Eligible Project Value

8M€ - 10M€

Maximum Duration

60 months

Dates & Deadlines

Publication Date

October 5, 2026

Opening Date

February 10, 2026

Fase única

September 16, 2027 at 05:00 PM GMT+2 (343 days left)

Description

Objectives

This topic aims to support the pre-commercial procurement (PCP) of innovative and affordable solutions for healthcare systems in the areas of cancer technologies, medical devices and medicines, contributing directly to the implementation of the EU Mission on Cancer . The objective is to accelerate the development and validation of breakthrough solutions that address unmet needs in cancer prevention, diagnosis, treatment and patient care, while helping public healthcare providers become early adopters of innovation. The action seeks to bring together healthcare procurers, clinicians, researchers, patients, industry and public authorities to jointly steer the development of innovative solutions capable of improving cancer outcomes and increasing the sustainability and resilience of healthcare systems.

Funding

Funding is provided under a Horizon Europe Pre-Commercial Procurement (PCP) action within the framework of the EU Mission on Cancer . The topic has an indicative budget of €26 million , with the European Commission expecting to fund three projects . The expected EU contribution ranges between €8 million and €10 million per project , although proposals requesting different amounts may be considered if adequately justified.

As a HORIZON-PCP (Pre-Commercial Procurement) action, the funding supports the procurement of research and development services aimed at developing and validating innovative solutions that are not yet commercially available. The action enables groups of public procurers and healthcare organisations to jointly steer the development of new cancer-related technologies, medical devices and therapeutic solutions that address unmet healthcare needs.

Eligible Expenses

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Eligibility

Eligible Sectors

Health & Life Sciences

Application Mode

Consortium / Copromotion

Company Typologies

- Micro
- SME
- Small Mid-Cap
- Mid-Cap

- Large
- Private non-profit entities
- Public entities

Action Types

- Pre-Commercial Procurement
- Clinical studies
- Translational research
- Prevention and early detection initiatives
- Therapy development
- Patient support

EU Programme Details

Call ID

HORIZON-MISS-2027-02-CANCER-05

Cluster

Mission

Destination

Cancer

Submission Mode

Single-stage

EU Contribution

Around €8,000,000.00 to €10,000,000.00 per project

Expected Projects

3

Funding Rate Rule

The action is funded under Horizon Europe PCP rules, which allow reimbursement of up to 100% of eligible project costs for the beneficiaries involved in the procurement action

Official Links

Official Regulation

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-05?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-05&isExactMatch=true&status=31094501,31094502,31094503>

Grantavia page

<https://grantavia.com/en/incentives/pre-commercial-procurement-of-affordable-solutions-for-healthcare-systems-in-the-areas-of-cancer-technologies-cancer-medical-devices-or-cancer-medicines>

Schedule a meeting

<https://calendly.com/sandra-cardoso-epsa/reuniao>